Navigation Links
FDA Grants Over-The-Counter Clearance to GentleWaves(R) for the First Home Use Light-Based Device to Treat Wrinkles
Date:2/25/2008

Clearance Opens Door For Home Use In The Anti-Aging Market

VIRGINIA BEACH, Va., Feb. 25 /PRNewswire-USNewswire/ -- Light BioScience(R), LLC, the leader in the science of LED (light emitting diode) Photomodulation, announced today that it has become the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for the treatment of periorbital wrinkles. This clearance paves the way for future development of a new anti-aging device to deliver the GentleWaves LED Photomodulation(R) technology directly to the consumer marketplace without a prescription.

Currently used by physicians around the world, GentleWaves has been scientifically proven to reduce the appearance of fine lines and wrinkles through the use of a patented system of pulsating amber-colored LEDs. These LEDs are specifically coded to stimulate collagen production while slowing down collagen breakdown(1). Invented by David H. McDaniel, M.D., director of the Institute of Anti-Aging Research and Assistant Professor of Clinical Dermatology and Plastic Surgery, Eastern Virginia Medical School, Virginia Beach, Va., the GentleWaves LED Photomodulation technology is a novel approach to provide skin rejuvenation without injuring the skin. GentleWaves is non-thermal, non-ablative and has no pain, side effects, or downtime.

"This clearance marks a significant milestone for our company as we continue to demonstrate our leadership in light-based science and break new ground in the medical professional and home use markets," comments Rick Krupnick, Chief Executive Officer of Light BioScience. "The opportunity to develop the first FDA cleared at-home, light-based device to treat wrinkles is just the first step in making this exciting technology more accessible to the public."

The future of GentleWaves is even more promising as its benefits expand beyond the anti-aging arena. Currently the Company is investigating
'/>"/>

SOURCE Light BioScience, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. U.S. Labor Department Awards $10.1 Million for Safety and Health Training Grants
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide
4. USAID Announces First Malaria Communities Program Grants
5. The Highmark Foundation Awards $580,000 in Highmark Healthy High 5 Grants to Four Non-Profit Organizations
6. KV Pharmaceutical Company Reports Results of Special Independent Committee Review of Stock Option Grants
7. FDA Grants Clearance to Langford IC Systems, Inc.
8. Dienst Custom Homes Grants Over 40 Wishes in Three Years
9. United Animal Nations Offers Financial Assistance Grants of up to $500 to Help Southern California Fire Victims Obtain Vet Care, Temporary Boarding for Pets
10. PA Health Department Awards Community Primary Care Challenge Grants
11. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Christopher Asandra, M.D., Founder and Chief Medical Officer of ... recent decision to issue a warning on testosterone ... are not supported by science, and that the warning ... “The FDA appears to have developed a case of ... “There is not nearly enough evidence to support the ...
(Date:3/4/2015)... TROY Healthcare Solutions will be introducing TROY ... level of security for prescriptions, in Houston, Texas on ... Center located at 6633 Travis Street from 7 AM ... TROY Healthcare Solutions will host a continental breakfast. Starting ... presentations each hour to introduce attendees to TROY Secure ...
(Date:3/4/2015)... 04, 2015 Cook For Your Life ... teaches healthy cooking to people touched by cancer, is ... The program, run by founder Ann Ogden, will be ... Management. The unique partnership will expand the program from ... CFYL in 2007. After going through her own cancer ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 Smokers across ... marketing campaign called 'We Love Smokers' from Aqua-Tine, the ... tobacco. , "It’s important to establish a clear ... to it. Our idea, 'We Love Smokers' elevates the ... of view. We created a bold tone of voice ...
(Date:3/4/2015)... Blake’s All Natural Foods , ... attend this year’s Natural Products Expo West in Anaheim, ... this new line, Blake’s, who has the top four ... its commitment to creating high-quality dishes that are easily ... the natural channel, Blake’s understands what educated consumers are ...
Breaking Medicine News(10 mins):Health News:NuMale’s Dr. Christopher Asandra: FDA Suffering from “Premature Equivocation” on Issue of Testosterone and Risks 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 2Health News:TROY Healthcare to Offer Prescription Solutions that can save a Hospital $100,000 3Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 2Health News:The Brand Behind The Bold and Provocative Ad Campaign 'We Love Smokers' 3Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 2Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 3
... some students experience while taking their exams may also affect ... allergy// , scientists say. ,Mats Lekander and other ... medical exam affects stress hormone levels, the immune system and ... ,The extensive tests were conducted on two occasions - first ...
... death toll from the ‘Typhoon Saomai’ has risen to 330. ... had increased// after 6 more bodies were discovered in the ... bodies were fished out from the sea, off the Shacheng ... 186. ,Cai Meisheng, vice mayor of Fuding, said ...
... eyesight, but according to a recent research, yellow and green vegetables ... be good for the eyesight. ,The diets of 1,700 American ... researchers at the University of Wisconsin to observe the affect of ... carried out by asking each woman what was her regular diet ...
... that getting married may benefit depressed people more than it ... beneficial to the general well being of a person, but ... health aspect of tying the knot. ,“Our findings question ... for all individuals,” observed co-author Adrianne Frech, a doctoral student ...
... child attending the Craigneuk Nursery Centre in Wishaw is recovering at ... O157 infection. ,The Craigneuk Nursery Centre cares for ... ,A NHS Lanarkshire, spokesman who refused to reveal ... children had been contacted as a precaution. ,A ...
... has touched the 25 year mark and this year ... With increasing// access to lifesaving treatments last year even ... reported declining HIV infection rates. However Bill Gates addressing ... that current trends don’t bode well for the future ...
Cached Medicine News:Health News:Yellow and green vegetables for better eyesight 2Health News:Need for Change in Social Norms to Prevent Spread of HIV 2Health News:Need for Change in Social Norms to Prevent Spread of HIV 3
(Date:3/4/2015)... Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), ... today announced its financial results for the fourth quarter ... 2014 Financial Highlights , Total sales in ... 36.8% excluding the impact of foreign currency exchange rate ... same quarter of 2013. , Gross profit increased ...
(Date:3/4/2015)... Mass., March 4, 2015 GSI Group Inc. ... "GSI"),  a global leader and supplier of precision photonics ... equipment and advanced industrial technology markets, today reported financial ... Unless otherwise noted, all financial results in this press ... Fourth QuarterDuring the fourth quarter of 2014, GSI ...
(Date:3/4/2015)... -- Alimera Sciences, Inc. (NASDAQ: ALIM ... the research, development and commercialization of prescription ophthalmic ... quarter and year ended December 31, 2014. ... for Alimera Sciences, most notably having received U.S. ... treatment of diabetic macular edema," said Dan Myers, ...
Breaking Medicine Technology:China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 10GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 11GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 12GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 13GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 14GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 15
... of Disease Activity as Measured,by MRI and Relapse ... May 1, 2007 -- Genentech, Inc.,(NYSE: DNA) ... from a Phase II clinical study of Rituxan®,(rituximab) in ... the American Academy of Neurology,annual meeting held in Boston. ...
... BOSTON--(BUSINESS WIRE)--May 1, 2007 - Significantly more patients,treated ... percent or,more compared with placebo, according to study ... annual meeting.,Clinically, this outcome would equate to a ... to moderate pain., Fibromyalgia is one of the ...
Cached Medicine Technology:Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6Lyrica Significantly Reduced Pain and Helped Patients Manage the,Symptoms of Fibromyalgia, Data Show 2Lyrica Significantly Reduced Pain and Helped Patients Manage the,Symptoms of Fibromyalgia, Data Show 3
Straight shafts with 4 mm platform. Wide serrated handle with dull finish. Platform straight....
Regular tip. 1 mm x 13 mm. Serrated. Insulated....
Straight shafts with fine tips and dull finish. Insulated stop with tip gap set at 0.3 mm. Smooth handle....
Curved shafts with 3.5 mm angled platform and dull finish. Wide serrated handle with dull finish....
Medicine Products: